Skip to main content
SpringerLink
Log in

Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis

A dose-response study

  • Liver: Cirrhosis, Fibrosis, Portal Hypertension, and Transplantation
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Tauroursodeoxycholic acid, a highly hydrophilic bile acid, may be of therapeutic value for chronic cholestatic liver diseases. We performed a dose-response study on 24 patients with primary biliary cirrhosis who were randomly assigned to receive 500, 1000, or 1500 mg daily of tauroursodeoxycholic acid for six months. Biliary enrichment with ursodeoxycholic acid ranged from 15% to 48% and was not related with the dose. Serum liver enzyme levels decreased significantly after the first month of treatment with all the three doses. No significant difference among the three doses was found, although further reduction over time occurred with 1000 and 1500 mg daily. Plasma total and HDL cholesterol significantly decreased in patients administered the two higher doses. Diarrhea was the only side effect. In conclusion, a dose of about 10 mg/kg body wt/day of tauroursodeoxycholic acid should be used for long-term studies in patients with primary biliary cirrhosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR: Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts:In vitro studies in rat hepatocytes and human erythrocytes. Hepatology 14:920–926, 1991

    Google Scholar 

  2. Heuman DM, Mills, AS, McCall J, Hylemon PB, Pandak WM, Vlahcevic ZR. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts.In vivo studies in the rat. Gastroenterology 100:203–211, 1991

    Google Scholar 

  3. Nakai T, Katagiri K, Hoshino N, Hayakawa T, Ohiwa T: Microtubule-independent choleresis and anti-cholestatic action of tauroursodeoxycholate in colchicine treated rat liver. Biochem J 288:613–617, 1992

    Google Scholar 

  4. Tsukahara K, Kanai S, Ohta M, Kitani K: Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats. Liver 13:262–269, 1993

    Google Scholar 

  5. Azer SA, Stacey NH: Hepatoprotection in ethinylestradioltreated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. Hepatology 18:311A, 1993 (abstract)

    Google Scholar 

  6. Rodrigues CMP, Kren BT, Steer CJ, Setchell KDR: Tauroursodeoxycholate increases rat liver ursodeoxycholate levels and limits lithocholate formation better than ursodeoxycholate. Gastroenterology 109:564–572, 1995

    Google Scholar 

  7. Armstrong MJ, Carey MC: The hydrophobic/hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J Lipid Res 23:70–80, 1982

    Google Scholar 

  8. Attili AF, Angelico M, Cantafora A, Alvaro D, Capocaccia L: Bile acid-induced liver toxicity: Relation to the hydrophobic-hydrophilic balance of bile acids. Med Hypotheses 19:57–69, 1986

    Google Scholar 

  9. Hofmann AF, Popper H: Ursodeoxycholic acid for primary biliary cirrhosis. Lancet 2:398–399, 1987

    Google Scholar 

  10. Heuman DM: Quantitative estimation of the hydrophobic-hydrophilic balance of mixed bile salt solutions. J Lipid Res 30:719–730, 1989

    Google Scholar 

  11. Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F: Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1:834–836, 1987

    Google Scholar 

  12. Leuschner U, Fischer H, Kurtz W, et al: Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled doubleblind trial. Gastroenterology 97:1268–1274, 1989

    Google Scholar 

  13. Battezzati PM, Podda M, Bianchi FB, et al: Ursodeoxycholic acid for symptomatic primary biliary cirrhosis: Preliminary analysis of a double-blind multicentre trial. J Hepatol 17:332–338, 1993

    Google Scholar 

  14. Chazouillères O, Poupon R, Capron JP, et al: Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 11:120–123, 1990

    Google Scholar 

  15. Beuers U, Spengler U, Kruis W, et al: Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: A placebocontrolled trial. Hepatology 16:707–714, 1992

    Google Scholar 

  16. Colombo C, Setchell KDR, Podda M, et al: Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 117:482–489, 1990

    Google Scholar 

  17. Poupon RE, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group: A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 325:1548–1554, 1991

    Google Scholar 

  18. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW: A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 9:162–168, 1994

    Google Scholar 

  19. Heathcote EJL, Cauch-Dudek K, Walker V, et al: The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19:1149–1156, 1994

    Google Scholar 

  20. Lindor KD, Dickson ER, Baldus WP, et al: Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 106:1284–1290, 1994

    Google Scholar 

  21. Combes B, Carithers RL Jr, Maddrey WC, et al: A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22:759–766, 1995

    Google Scholar 

  22. Poupon RE, Poupon R, Balkau B, UDCA-PBC Study Group: Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 330:1342–1347, 1994

    Google Scholar 

  23. Batta AK, Salen G, Shefer S, Tint GS, Dayal B: The effect of tauroursodeoxycholic acid and taurine supplementation on biliary bile acid composition. Hepatology 2:811–816, 1982

    Google Scholar 

  24. Taal BG, Schalm SW, ten Kate FWJ, Hermans J, Geertzen RGM, Feltkamp BEW: Clinical diagnosis of primary biliary cirrhosis: A classification based on major and minor criteria. Hepatogastroenterology 30:178–182, 1983

    Google Scholar 

  25. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York McGraw-Hill, 1971, pp 220–228

    Google Scholar 

  26. Vonk RJ, Kneepkens CMF, Havinga R, Kuipers F, Bijleveld CMA: Enterohepatic circulation in man: A simple method for the determination of duodenal bile acids. J Lipid Res 27:901–904, 1986

    Google Scholar 

  27. Rossi SS, Converse JL, Hofmann AF: High-pressure liquid chromatographic analysis of conjugated bile acids in human bile: Simultaneous resolution of sulphated and unsulphated lithocholyl amidates and the common conjugated bile acids. J Lipid Res 28:589–595, 1987

    Google Scholar 

  28. Setchell KDR, Worthington J: A rapid method for the quantitative extraction of bile acids and their conjugates from serum using commercially available reverse phase octadecylsilane bonded silica cartridge. Clin Chim Acta 125:135–144, 1982

    Google Scholar 

  29. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York: McGraw-Hill, 1971, pp. 514–603

    Google Scholar 

  30. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971, pp 196–201

    Google Scholar 

  31. Street JM, Setchell KDR: Chromatographic methods for bile acid analysis. Biomed Chromatogr 2:229–241, 1988

    Google Scholar 

  32. Setchell KDR, Rodrigues C, Podda M, Crosignani A: Metabolism of tauroursodeoxycholic acid given by mouth in patients with primary biliary cirrhosis. Gut 1996 (in press)

  33. Podda M, Ghezzi C, Battezzati PM, et al: Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 34:59S-65S, 1989

    Google Scholar 

  34. Crosignani A, Podda M, Battezzati PM, et al: Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 14:1000–1007, 1991

    Google Scholar 

  35. Walker S, Stiehl A, Raedsch R, Kloters P, Kommerell B: Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat jejunum, ileum, and colon. Digestion 32:47–52, 1985

    Google Scholar 

  36. Ota M, Minami Y, Hoshita T: Intestinal absorption of ursodeoxycholic, glycoursodeoxycholic and tauroursodeoxycholic acids in rats. J Pharmacobio-Dyn 8:114–118, 1985

    Google Scholar 

  37. Poupon R, Chrétien Y, Parquet M, Ballet F, Rey C, Infante R: Hepatic transport of bile acids in the isolated perfused rat liver. Structure-kinetic relationship. Biochem Pharmacol 37:209–212, 1988

    Google Scholar 

  38. Aldini R, Roda A, Simioni P, Lenzi P, Roda E: Uptake of bile acids by perfused rat liver: Evidence of structure-activity relationship. Hepatology 10:840–845, 1989

    Google Scholar 

  39. Jazrawi RP, de Caestecker JS, Goggin PM, et al: Kinetics of hepatic bile acids handling in cholestatic liver disease: Effect of ursodeoxycholic acid. Gastroenterology 106:134–142, 1994

    Google Scholar 

  40. Poupon RE, Ouguerram K, Chrétien Y, et al: Cholesterolowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. Hepatology 17:577–582, 1993

    Google Scholar 

  41. Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I. Dig Dis Sci 27:737–761, 1982

    Google Scholar 

  42. Bachrach WH, Hofmann AF: Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II. Dig Dis Sci 27:833–856, 1982

    Google Scholar 

  43. Ponz de Leon M, Carulli N, Loria P, Ioria R, Zironi F: Cholesterol absorption during bile acid feeding. Effect of ursodeoxycholic acid (UDCA) administration. Gastroenterology 78:214–219, 1980

    Google Scholar 

  44. Roda A, Grigolo B, Pellicciari R, Natalini B: Structure-activity relationship studies on natural and synthetic bile acid analogs. Dig Dis Sci 34:24S-35S, 1989

    Google Scholar 

  45. Hofmann AF: Chemistry and enterohepatic circulation of bile acids. Hepatology 4:4S-14S, 1984

    Google Scholar 

  46. Hofmann AF, Roda A: Physicochemical properties of bile acids and their relationship to biological properties: An overview of the problem. J Lipid Res 25:1477–1489, 1984

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Internal Medicine, School of Medicine, Ospedale San Paolo, Institute of Internal Medicine I, University of Milan, Italy

    Andrea Crosignani MD, Pier Maria Battezzati MD, Kenneth D. R. Setchell PhD, Pietro Invernizzi MD, Giovanni Covini MD, Massimo Zuin MD & Mauro Podda MD

  2. Clinical Mass Spectrometry Laboratory, Children's Hospital Medical Center, Cincinnati, Ohio

    Andrea Crosignani MD, Pier Maria Battezzati MD, Kenneth D. R. Setchell PhD, Pietro Invernizzi MD, Giovanni Covini MD, Massimo Zuin MD & Mauro Podda MD

Authors
  1. Andrea Crosignani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pier Maria Battezzati MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenneth D. R. Setchell PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pietro Invernizzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Covini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Massimo Zuin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mauro Podda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crosignani, A., Battezzati, P.M., Setchell, K.D.R. et al. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. Digest Dis Sci 41, 809–815 (1996). https://doi.org/10.1007/BF02213140

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02213140

Key Words

Search

Navigation